918-P: Effect of Remogliflozin in Improving NYHA Class Compared with Empagliflozin in Type 2 Diabetes Patients with Heart Failure (Remit HF)

• DOI: 10.2337/db24-918-p
• Publication Date: 2024-06-14T07:30:59Z
• Authors: HANMANT V. BARKATE; YASH PANCHAL; SUMIT BHUSHAN; SANJAY Y. CHOUDHARI; ANUP U. PETARE
• Keywords: Empagliflozin

Background: In patient of T2DM and HF, reduced ejection fraction (HFrEF) constitutes the majority HF cases, posing significant risk mortality. NYHA classification, recommended in global guidelines, independently predicts SGLT2i have shown to reduce incidence hospitalization for HF. Hence, this study was planned evaluate effectiveness Remogliflozin improving class patients with Methods: prospective, multicentre study, 250 HFrEF having Class I III, were enrolled. 125 allocated each (R) Empagliflozin (E) group. Results: Baseline distribution comparable both groups. At baseline, 4%, 78.4%, 17.6% R-group I, II, III respectively, which improved 50.91% 42.73% 6.36% at week 24 (Figure 1). Similarly, E-group, about 4.8%, 64.8%, 30.4% 48.5% 40.9% 10.5% 24. Percentage improvement by ≥1 grade seen R E-group (80% vs 76%) weeks. The positive indicates that treatment provided patient’s function QoL. Both groups showed echo parameters (LVEF, LVdd) no new safety concerns reported. Conclusion: between (HFrEF). These clinical benefits irrespective baseline associated early sustained over duration. Disclosure H.V. Barkate: Employee; Glenmark Pharmaceuticals. Y. Panchal: None. S. Bhushan: S.Y. Choudhari: Pharmaceuticals, Sun Pharmaceutical Industries Ltd. A.U. Petare: